{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"The maximum tolerated dose of TRC102 in combination with 500mg/m\\^2 IV of Pemetrex and 60 or 75 mg/m\\^2 IV of Cisplatin is based on toxicities observed during the first cycle and is defined as the highest dose tested in which fewer than 33% of patients experience an attributable DLT to the study drug, when at least 6 patients are treated at that dose and are evaluable for toxicity. Dose escalations proceeded according to a standard 3+3 design.","groups":[{"description":"Patients receive starting dose of TRC102 50 mg/day PO on days 1-4, 500 mg/m\\^2 pemetrexed disodium IV over 10 minutes, and 60 or 75 mg/m\\^2 of cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue TRC102 and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.\n\nCisplatin: Given IV\n\nTRC102: Given PO\n\nPemetrexed Disodium: Given IV","id":"OG000","title":"Treatment (TRC102, Pemetrexed Disodium, Cisplatin)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"21 days from start of treatment, up to 2 years","title":"Maximum Tolerated Dose (MTD)","type":"PRIMARY","unitOfMeasure":"mg/day"}